Busca avançada
Ano de início

Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms

Texto completo
Vicari, Hugo Passos ; Lima, Keli ; Costa-Lotufo, Leticia Veras ; Machado-Neto, Joao Agostinho
Número total de Autores: 4
Tipo de documento: Artigo Científico
Fonte: CANCERS; v. 14, n. 24, p. 15-pg., 2022-12-01.

Simple Summary Hematologic neoplasms comprise a heterogeneous group of diseases that interfere with normal blood production. Treating patients who fail available therapies for these diseases is an ongoing challenge. Thus, the search for new treatment options is urgent, and drug repositioning is emerging as an attractive strategy for finding new effective drugs. Eribulin is a drug that acts on microtubules, and it is used in solid tumors, and its safety is known. In the present study, we provide evidence of the effects of eribulin on hematologic cancers and identify the potential biomarkers of responsiveness. Our study indicates that eribulin is a candidate blood cancer drug for repositioning. Despite the advances in understanding the biology of hematologic neoplasms which has resulted in the approval of new drugs, the therapeutic options are still scarce for relapsed/refractory patients. Eribulin is a unique microtubule inhibitor that is currently being used in the therapy for metastatic breast cancer and soft tissue tumors. Here, we uncover eribulin's cellular and molecular effects in a molecularly heterogeneous panel of hematologic neoplasms. Eribulin reduced cell viability and clonogenicity and promoted apoptosis and cell cycle arrest. The minimal effects of eribulin observed in the normal leukocytes suggested selectivity for malignant blood cells. In the molecular scenario, eribulin induces DNA damage and apoptosis markers. The ABCB1, ABCC1, p-AKT, p-NF kappa B, and NF kappa B levels were associated with responsiveness to eribulin in blood cancer cells, and a resistance eribulin-related target score was constructed. Combining eribulin with elacridar (a P-glycoprotein inhibitor), but not with PDTC (an NFkB inhibitor), increases eribulin-induced apoptosis in leukemia cells. In conclusion, our data indicate that eribulin leads to mitotic catastrophe and cell death in blood cancer cells. The expression and activation of MDR1, PI3K/AKT, and the NF kappa B-related targets may be biomarkers of the eribulin response, and the combined treatment of eribulin and elacridar may overcome drug resistance in these diseases. (AU)

Processo FAPESP: 21/01460-1 - Investigação do potencial antineoplásico de novos fármacos que modulam a dinâmica de microtúbulos em Leucemia Mieloide Aguda
Beneficiário:Hugo Passos Vicari
Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
Processo FAPESP: 19/23864-7 - Análise compreensiva de dados genômicos para identificação e validação de novos alvos terapêuticos envolvidos na regulação de citoesqueleto celular em Leucemias agudas
Beneficiário:João Agostinho Machado Neto
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 19/01700-2 - Investigação funcional de Stathmin 1 na proliferação, diferenciação e apoptose em modelo de leucemia promielocítica aguda
Beneficiário:Hugo Passos Vicari
Modalidade de apoio: Bolsas no Brasil - Mestrado
Processo FAPESP: 21/11606-3 - Investigação dos efeitos antineoplásicos de novos inibidores de PIP4K2 e HDAC em neoplasias hematológicas
Beneficiário:João Agostinho Machado Neto
Modalidade de apoio: Auxílio à Pesquisa - Regular